Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Enhance Shareholder Value

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has taken a significant step towards optimizing its market presence by announcing a 1-for-12 reverse stock split of its common stock. This decision, set to take effect on August 5, 2025, was approved by shareholders on July 9 and subsequently ratified by the board on July 11. The move is designed to refine market dynamics, attract a broader investor base, and ensure trading conditions are more closely aligned with the interests of shareholders.

Post-split, the company's shares will continue to trade on the NYSE American under the ticker symbol 'CLDI,' but with a new CUSIP number of 320703 408. The reverse stock split mechanism will convert every 12 pre-split shares into one post-split share. To ensure fairness, fractional shares will be rounded up to the nearest whole share at the participant level. This adjustment will also proportionally impact outstanding options, warrants, and equity plan shares, although it leaves the par value and the number of authorized shares unchanged.

This strategic initiative underscores Calidi Biotherapeutics' dedication to enhancing shareholder value and securing a stronger position in the highly competitive biotechnology sector. By adjusting its stock structure, the company aims to create a more favorable environment for future growth and investment opportunities. For those seeking more information, further details on the reverse stock split can be found in the full press release available here.